Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Streptococcal Vaccines: Current Status and Future Directions
share announcement

Streptococcal Vaccines: Current Status and Future Directions

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 July 2026 | Viewed by 2253

Special Issue Editor

Dr. Mariusz Skwarczynski

E-Mail Website
Guest Editor
School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
Interests: vaccines and nanomedicine; vaccine design; nanotechnology; peptide chemistry; medicinal chemistry; vaccine/drug delivery; antimicrobial agents; macromolecules; adjuvants; immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to submit an article to this Special Issue titled “Streptococcal Vaccines: Current Status and Future Directions”.  The submission deadline is 31 July 2026.

Streptococcal infections are among the most common bacterial infections. Among Streptococcal species, three are of significant concern: (a) Group B Streptococcus (GBS), causing serious infections like pneumonia, sepsis, and meningitis; (b) Streptococcus pneumoniae, causing a common community-acquired pneumonia, particularly in young children and the elderly; and (c) Group A Streptococcus (GAS), causing strep throat, skin and bloodstream infections, and deadly rheumatic heart diseases. Vaccines against S. pneumoniae are available (e.g., Prevenar 13, Pneumovax 23); however, they do not offer universal protection, while vaccines against other streptococci are in development. Given the global spread, growing antibiotic resistance, and high mortality rate related to systemic infections and autoimmune postinfection complications, the need for the development of vaccines against these bacteria is of high priority.

In this Special Issue, original research articles and reviews are welcome and may include the following topics:

  1. Vaccine development against Group A or B Streptococcus;
  2. Vaccines targeting other Streptococcal species;
  3. Adjuvants in streptococcal vaccines;
  4. Animal models for streptococcal vaccines;
  5. Clinical trials on the Streptococcal vaccines.

We look forward to receiving your contributions.

Dr. Mariusz Skwarczynski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • group A, B streptococcus
  • Streptococcus pneumoniae
  • streptococcal vaccines
  • streptococcal antigens
  • adjuvants
  • animal models
  • clinical trials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 760 KB  
Article
A Multi-Country Comparison of Number Needed to Vaccinate for PCV20 and PCV15 in Infants
by Euan Dawson, Maria J. Tort, An Ta and Mark H. Rozenbaum
Vaccines 2026, 14(2), 188; https://doi.org/10.3390/vaccines14020188 - 18 Feb 2026
Cited by 1 | Viewed by 1556 | Correction
Abstract
Background/Objectives: Infant pneumococcal conjugate vaccines (PCV) have significantly reduced pneumococcal morbidity and mortality. Newer vaccines, 15-valent (PCV15) and 20-valent (PCV20), offer broader serotype coverage, potentially preventing more disease. This study estimated the number needed to vaccinate (NNV) to prevent one disease outcome for [...] Read more.
Background/Objectives: Infant pneumococcal conjugate vaccines (PCV) have significantly reduced pneumococcal morbidity and mortality. Newer vaccines, 15-valent (PCV15) and 20-valent (PCV20), offer broader serotype coverage, potentially preventing more disease. This study estimated the number needed to vaccinate (NNV) to prevent one disease outcome for infant PCV20 and PCV15 programs versus 13-valent PCV (PCV13). Countries from Europe, the Asia-Pacific, and the Americas were included. Methods: A multi-cohort, population-based model estimated the cumulative NNVs for infant programs with PCV20 and PCV15 relative to PCV13 in 21 countries. Outcomes included overall pneumococcal case, hospitalization, and death. The ratio of PCV15 NNVs to PCV20 NNVs was calculated. Probabilistic sensitivity analysis (PSA) and scenario assessments tested results’ robustness. Results: Across 21 countries, the median of country-specific NNV estimates to prevent one pneumococcal case was 13 with PCV20 and 80 with PCV15. Median NNVs to prevent a hospitalization or death were 44 and 568 with PCV20 and 203 and 2203 with PCV15, respectively. PCV20 demonstrated lower NNVs than PCV15 across all countries and outcomes. Median NNV ratios for PCV15 versus PCV20 were 5.1 (case), 4.5 (hospitalization), and 4.2 (death). No clear geographic differences were observed. PSA and scenario analyses indicated stable results with minimal deviations. Conclusions: Infant immunization with PCV20 is associated with lower NNVs than PCV15. To achieve the same disease reduction as PCV20, over five times as many children would need to be vaccinated with PCV15. These findings suggest PCV20 may offer greater public health impact compared with PCV15 in infant immunization programs. Full article
(This article belongs to the Special Issue Streptococcal Vaccines: Current Status and Future Directions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop